Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials

Carmen Radecki Breitkopf, Melissa Loza, Kathleen Vincent, Thomas Moench, Lawrence R. Stanberry, Susan L. Rosenthal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Developing effective and safe microbicides requires study procedures (e.g., technology used, abstinence requirements, and product use) that are acceptable to participants. Methods: Thirty women completed 4 study visits including pelvic examination, colposcopy, optical coherence tomography (OCT), and semistructured, qualitative interviews. Additional requirements included abstinence (for approximately 16 days) and twice daily vaginal product use (for 5.5 days). Interviews were audio-recorded, transcribed, and analyzed using framework analysis. Themes addressing OCT experiences, acceptability of abstinence, and vaginal product use were examined. Results: OCT was viewed favorably as an imaging technology. Some women reported feeling the fiber-optic probe "poking" them and more than one-third spontaneously reported feeling pressure or pinching upon rotation of the speculum in connection with the OCT evaluation. Compliance with vaginal gel use was high, but for many women assigned to use a product containing nonoxynol-9 (vs. placebo), the postproduct use examination was more uncomfortable, relative to the initial examination or 1 week following product discontinuation. Nearly all women experienced product leakage; acceptability of leakage varied. Two women were not abstinent and several more found abstinence challenging. Some women involved their partner in decision making regarding trial enrollment. Strategies to remain abstinent included participating when the partner was away, avoiding early intimacy, and engaging in alternative sexual activities. Conclusions: Qualitative interviews in early-phase studies provide insights and capture information that would be missed by behavioral inference alone. Understanding participant's experiences is important in order to provide anticipatory guidance and plan future microbicide studies that facilitate adherence with trial requirements.

Original languageEnglish (US)
Pages (from-to)28-31
Number of pages4
JournalSexually Transmitted Diseases
Volume39
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Optical Coherence Tomography
Anti-Infective Agents
Safety
Interviews
Emotions
Nonoxynol
Foams and Jellies Vaginal Creams
Technology
Gynecological Examination
Colposcopy
Surgical Instruments
Sexual Behavior
Decision Making
Placebos
Pressure

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials. / Radecki Breitkopf, Carmen; Loza, Melissa; Vincent, Kathleen; Moench, Thomas; Stanberry, Lawrence R.; Rosenthal, Susan L.

In: Sexually Transmitted Diseases, Vol. 39, No. 1, 01.2012, p. 28-31.

Research output: Contribution to journalArticle

Radecki Breitkopf, Carmen ; Loza, Melissa ; Vincent, Kathleen ; Moench, Thomas ; Stanberry, Lawrence R. ; Rosenthal, Susan L. / Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials. In: Sexually Transmitted Diseases. 2012 ; Vol. 39, No. 1. pp. 28-31.
@article{a52520a061044324a325127c061cd0ed,
title = "Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials",
abstract = "Background: Developing effective and safe microbicides requires study procedures (e.g., technology used, abstinence requirements, and product use) that are acceptable to participants. Methods: Thirty women completed 4 study visits including pelvic examination, colposcopy, optical coherence tomography (OCT), and semistructured, qualitative interviews. Additional requirements included abstinence (for approximately 16 days) and twice daily vaginal product use (for 5.5 days). Interviews were audio-recorded, transcribed, and analyzed using framework analysis. Themes addressing OCT experiences, acceptability of abstinence, and vaginal product use were examined. Results: OCT was viewed favorably as an imaging technology. Some women reported feeling the fiber-optic probe {"}poking{"} them and more than one-third spontaneously reported feeling pressure or pinching upon rotation of the speculum in connection with the OCT evaluation. Compliance with vaginal gel use was high, but for many women assigned to use a product containing nonoxynol-9 (vs. placebo), the postproduct use examination was more uncomfortable, relative to the initial examination or 1 week following product discontinuation. Nearly all women experienced product leakage; acceptability of leakage varied. Two women were not abstinent and several more found abstinence challenging. Some women involved their partner in decision making regarding trial enrollment. Strategies to remain abstinent included participating when the partner was away, avoiding early intimacy, and engaging in alternative sexual activities. Conclusions: Qualitative interviews in early-phase studies provide insights and capture information that would be missed by behavioral inference alone. Understanding participant's experiences is important in order to provide anticipatory guidance and plan future microbicide studies that facilitate adherence with trial requirements.",
author = "{Radecki Breitkopf}, Carmen and Melissa Loza and Kathleen Vincent and Thomas Moench and Stanberry, {Lawrence R.} and Rosenthal, {Susan L.}",
year = "2012",
month = "1",
doi = "10.1097/OLQ.0b013e318231575f",
language = "English (US)",
volume = "39",
pages = "28--31",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials

AU - Radecki Breitkopf, Carmen

AU - Loza, Melissa

AU - Vincent, Kathleen

AU - Moench, Thomas

AU - Stanberry, Lawrence R.

AU - Rosenthal, Susan L.

PY - 2012/1

Y1 - 2012/1

N2 - Background: Developing effective and safe microbicides requires study procedures (e.g., technology used, abstinence requirements, and product use) that are acceptable to participants. Methods: Thirty women completed 4 study visits including pelvic examination, colposcopy, optical coherence tomography (OCT), and semistructured, qualitative interviews. Additional requirements included abstinence (for approximately 16 days) and twice daily vaginal product use (for 5.5 days). Interviews were audio-recorded, transcribed, and analyzed using framework analysis. Themes addressing OCT experiences, acceptability of abstinence, and vaginal product use were examined. Results: OCT was viewed favorably as an imaging technology. Some women reported feeling the fiber-optic probe "poking" them and more than one-third spontaneously reported feeling pressure or pinching upon rotation of the speculum in connection with the OCT evaluation. Compliance with vaginal gel use was high, but for many women assigned to use a product containing nonoxynol-9 (vs. placebo), the postproduct use examination was more uncomfortable, relative to the initial examination or 1 week following product discontinuation. Nearly all women experienced product leakage; acceptability of leakage varied. Two women were not abstinent and several more found abstinence challenging. Some women involved their partner in decision making regarding trial enrollment. Strategies to remain abstinent included participating when the partner was away, avoiding early intimacy, and engaging in alternative sexual activities. Conclusions: Qualitative interviews in early-phase studies provide insights and capture information that would be missed by behavioral inference alone. Understanding participant's experiences is important in order to provide anticipatory guidance and plan future microbicide studies that facilitate adherence with trial requirements.

AB - Background: Developing effective and safe microbicides requires study procedures (e.g., technology used, abstinence requirements, and product use) that are acceptable to participants. Methods: Thirty women completed 4 study visits including pelvic examination, colposcopy, optical coherence tomography (OCT), and semistructured, qualitative interviews. Additional requirements included abstinence (for approximately 16 days) and twice daily vaginal product use (for 5.5 days). Interviews were audio-recorded, transcribed, and analyzed using framework analysis. Themes addressing OCT experiences, acceptability of abstinence, and vaginal product use were examined. Results: OCT was viewed favorably as an imaging technology. Some women reported feeling the fiber-optic probe "poking" them and more than one-third spontaneously reported feeling pressure or pinching upon rotation of the speculum in connection with the OCT evaluation. Compliance with vaginal gel use was high, but for many women assigned to use a product containing nonoxynol-9 (vs. placebo), the postproduct use examination was more uncomfortable, relative to the initial examination or 1 week following product discontinuation. Nearly all women experienced product leakage; acceptability of leakage varied. Two women were not abstinent and several more found abstinence challenging. Some women involved their partner in decision making regarding trial enrollment. Strategies to remain abstinent included participating when the partner was away, avoiding early intimacy, and engaging in alternative sexual activities. Conclusions: Qualitative interviews in early-phase studies provide insights and capture information that would be missed by behavioral inference alone. Understanding participant's experiences is important in order to provide anticipatory guidance and plan future microbicide studies that facilitate adherence with trial requirements.

UR - http://www.scopus.com/inward/record.url?scp=83555165931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555165931&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e318231575f

DO - 10.1097/OLQ.0b013e318231575f

M3 - Article

C2 - 22183842

AN - SCOPUS:83555165931

VL - 39

SP - 28

EP - 31

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 1

ER -